GENELUX CORPORATION Increase (Decrease) in Accounts Payable and Accrued Liabilities
GENELUX CORPORATION (GNLX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- GENELUX CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $825.00K.
- GENELUX CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $1.74M, a 55.37% increase year-over-year.
- GENELUX CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $374.00K, a 79.41% decline year-over-year.
- GENELUX CORPORATION increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$2.04M.
- GENELUX CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$1.21M, a 156.26% decline from fiscal 2024.
- GENELUX CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $2.16M.
- GENELUX CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$2.36M, a 201.95% decline from fiscal 2022.
- GENELUX CORPORATION increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.31M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $825.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.56M 10-Q · filed 2026-08-13 | $2.94M derived: sum of 3 quarters · filed 2026-08-13 | $896.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.74M 10-Q · filed 2026-05-07 | $2.11M derived: sum of 2 quarters · filed 2026-05-07 | $71.00K derived: sum of 3 quarters · filed 2026-05-07 | -$594.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$1.67M derived: sum of 2 quarters · filed 2026-03-19 | -$2.33M derived: sum of 3 quarters · filed 2026-08-13 | -$1.21M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$2.71M derived: sum of 2 quarters · filed 2026-08-13 | -$1.59M 10-Q · filed 2025-11-05 | $229.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$665.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $453.00K 10-Q · filed 2026-08-13 | $2.27M derived: sum of 3 quarters · filed 2026-08-13 | $1.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.12M 10-Q · filed 2026-05-07 | $2.93M derived: sum of 2 quarters · filed 2026-05-07 | $2.27M derived: sum of 3 quarters · filed 2026-05-07 | $1.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.15M derived: sum of 2 quarters · filed 2026-03-19 | $627.00K derived: sum of 3 quarters · filed 2026-03-19 | $2.16M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$662.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.19M derived: sum of 2 quarters · filed 2025-11-05 | $340.00K 10-Q · filed 2025-11-05 | $115.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$527.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.00M 10-Q · filed 2025-08-07 | $777.00K derived: sum of 3 quarters · filed 2025-08-07 | $302.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.53M 10-Q · filed 2025-05-06 | $1.30M derived: sum of 2 quarters · filed 2025-05-06 | $829.00K derived: sum of 3 quarters · filed 2025-05-06 | $84.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$700.00K derived: sum of 2 quarters · filed 2025-03-28 | -$1.45M derived: sum of 3 quarters · filed 2025-03-28 | -$2.36M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$475.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.22M derived: sum of 2 quarters · filed 2024-11-14 | -$2.13M 10-Q · filed 2024-11-14 | -$710.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$745.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.66M 10-Q · filed 2024-08-14 | -$235.00K derived: sum of 3 quarters · filed 2024-08-14 | -$285.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$913.00K 10-Q · filed 2024-05-09 | $510.00K derived: sum of 2 quarters · filed 2024-05-09 | $460.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.39M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.37M derived: sum of 2 quarters · filed 2024-03-29 | $2.31M derived: sum of 3 quarters · filed 2024-03-29 | $2.31M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $883.00K derived: sum of 2 quarters · filed 2023-11-14 | $890.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $933.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $940.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $7.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |